Biomm S.A Total Liabilities
Biomm S.A total liabilities. Based on the latest financial reports, Biomm S.A (BIOM3) has total liabilities worth R$200.93 Million BRL (≈ $39.43 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Biomm S.A liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomm S.A (2004–2024)
Total liabilities of Biomm S.A from 2004 to 2024. This chart illustrates how Biomm S.A's total liabilities have evolved over time, based on quarterly financial data. Explore Biomm S.A long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biomm S.A Competitors by Total Liabilities
The table below lists competitors of Biomm S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gia Lai Electricity JSC
VN:GEG
|
Vietnam | ₫8.69 Trillion |
|
Nordic Halibut AS
OL:NOHAL
|
Norway | Nkr853.22 Million |
|
Karsan Otomotiv Sanayi ve Ticaret AS
IS:KARSN
|
Turkey | TL13.56 Billion |
|
Bioversys AG
SW:BIOV
|
Switzerland | CHF32.07 Million |
|
SANIONA AB (PUBL)
F:30S
|
Germany | €44.58 Million |
|
LaFayette Acquisition Corp. Ordinary Share
NASDAQ:LAFA
|
USA | $4.14 Million |
|
LongDa Construction & Development Corp
TW:5519
|
Taiwan | NT$8.59 Billion |
|
Cti Logistics Ltd
AU:CLX
|
Australia | AU$183.00 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Biomm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Biomm S.A.
Liquidity & Leverage Metrics
Biomm S.A Total Liabilities Ratios Explained
Biomm S.A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.11 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomm S.A (2004–2024)
The table below shows the annual total liabilities of Biomm S.A from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | R$202.88 Million ≈ $39.81 Million |
-8.52% |
| 2023-12-31 | R$221.76 Million ≈ $43.51 Million |
-9.85% |
| 2022-12-31 | R$245.98 Million ≈ $48.27 Million |
-4.75% |
| 2021-12-31 | R$258.25 Million ≈ $50.67 Million |
+6.06% |
| 2020-12-31 | R$243.49 Million ≈ $47.78 Million |
+3.52% |
| 2019-12-31 | R$235.21 Million ≈ $46.15 Million |
+17.85% |
| 2018-12-31 | R$199.59 Million ≈ $39.16 Million |
-1.72% |
| 2017-12-31 | R$203.09 Million ≈ $39.85 Million |
+18.45% |
| 2016-12-31 | R$171.46 Million ≈ $33.64 Million |
+49.68% |
| 2015-12-31 | R$114.55 Million ≈ $22.48 Million |
+58.07% |
| 2014-12-31 | R$72.46 Million ≈ $14.22 Million |
+148.65% |
| 2013-12-31 | R$29.14 Million ≈ $5.72 Million |
+0.48% |
| 2012-12-31 | R$29.00 Million ≈ $5.69 Million |
+44.59% |
| 2011-12-31 | R$20.06 Million ≈ $3.94 Million |
+123.68% |
| 2010-12-31 | R$8.97 Million ≈ $1.76 Million |
-15.96% |
| 2009-12-31 | R$10.67 Million ≈ $2.09 Million |
-56.24% |
| 2008-12-31 | R$24.39 Million ≈ $4.78 Million |
+104.31% |
| 2007-12-31 | R$11.94 Million ≈ $2.34 Million |
+47.94% |
| 2006-12-31 | R$8.07 Million ≈ $1.58 Million |
-36.13% |
| 2005-12-31 | R$12.63 Million ≈ $2.48 Million |
+137.98% |
| 2004-12-31 | R$5.31 Million ≈ $1.04 Million |
-- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more